- Home
- TSI vs IMUX Comparison
TSI vs IMUX Comparison
Compare TSI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | IMUX |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.7M | 209.2M |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TSI | IMUX |
|---|---|---|
| Price | $4.40 | $14.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 154.3K | 135.5K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $0.51 |
| 52 Week High | $5.06 | $15.84 |
Technical Indicators
Market Signals| Indicator | TSI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 54.02 |
| Support Level | N/A | $14.13 |
| Resistance Level | $4.46 | $15.82 |
| Average True Range (ATR) | 0.03 | 0.91 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 59.43 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.